Poractant Alfa Intratracheal Suspension [Curosurf] — Competitive Intelligence Brief

Poractant Alfa Intratracheal Suspension [Curosurf] (Poractant Alfa Intratracheal Suspension [Curosurf]) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Surfactant replacement therapy. Area: Respiratory.

phase 3 Surfactant replacement therapy Respiratory Small molecule

Target snapshot

Poractant Alfa Intratracheal Suspension [Curosurf] (Poractant Alfa Intratracheal Suspension [Curosurf]) — Hospital Clinic of Barcelona. Poractant alfa is a surfactant replacement therapy that helps to reduce the surface tension in the lungs, facilitating easier breathing.

Comparator set (3 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Poractant Alfa Intratracheal Suspension [Curosurf] TARGET	Poractant Alfa Intratracheal Suspension [Curosurf]	Hospital Clinic of Barcelona	phase 3	Surfactant replacement therapy
Bolus surfactant	Bolus surfactant	Zekai Tahir Burak Women's Health Research and Education Hospital	marketed	Pulmonary surfactant replacement therapy
Poractant alfa (Curosurf®)	Poractant alfa (Curosurf®)	Chiesi Farmaceutici S.p.A.	marketed	Pulmonary surfactant replacement therapy
Surfactant nebulisation	Surfactant nebulisation	University of Zurich	phase 3	Pulmonary surfactant replacement therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Surfactant replacement therapy class)

1. Hospital Clinic of Barcelona · 1 drug in this class